Sickle cell disease community is hopeful that genome editing will rechart course of the disease

In the first study of its kind, NHGRI researchers explored patients', parents' and physicians' perspectives on the use of CRISPR-Cas9 gene-editing to reverse sickle cell disease. Study participants expressed overall optimism about participating in human genome editing clinical trials, but were concerned about treatment risks and transparency of the research enterprise, according to the findings published December 24 inGenetics in Medicine.
Source: NHGRI Homepage Highlights - Category: Genetics & Stem Cells Source Type: news